Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts

Bellicum Pharma Comm (NASDAQ: BLCM)

$13.37 USD -$0.45 (-3.26%)
Last Price $13.37
Net Change $-0.45 (-3.26%)
Bid $0
Ask Price $0
Open Price $13.78
Previous Close Price $13.82
High Price $13.95
Low Price $13.11
Number of Trades 2,288
Volume 918,807
Fifty Two Week High $23.11 (2016-11-14)
Fifty Two Week Low $8.61 (2016-05-06)
Average Daily Volume 542,296
Share Outstanding 32,160 Shares
Total Dividend Payout 0/yr
Dividend Yield 0%
1st Quarter Earnings $-0.74 (2017-03-13)
2nd Quarter Earnings $-0.66 (2016-11-09)
3nd Quarter Earnings $-0.61 (2016-08-08)
4th Quarter Earnings $-0.56 (2016-05-09)
PE Ratio $0
EPS Growth $-5.11
Recent Earnings $-0.74
Annual EPS $-2.57
Last Quarter EPS $
Market Capitalization $0.43B
Insider Shareholders % 0.233%
Annual Revenue $0B
No. Shares Outstanding 32,160
Inst. Shareholder % 61.13%
Annual Net Income $0B
TTM Net Profit Margin $100.54
1-Year Return 31.85%
3-Year Return -44.01%
5-Year Return -44.01%
5-Year Revenue Growth 0%
5-Year Earnings Growth 0%
5-Year Dividend Growth 0%
Annual Dividend $0
Annual Dividend Yield 0%
Change in EPS YTD -5.11%
Dividends per Share $
Stock Split Ratio
Beta 1.33
Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company's lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials. It is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Bellicum Pharmaceuticals, Inc. is based in Houston, Texas.